Radiation Toxicity Treatment Market Report 2026

Radiation Toxicity Treatment Market Overview

• Radiation Toxicity Treatment market size has reached to $3.98 billion in 2025 • Expected to grow to $5.37 billion in 2030 at a compound annual growth rate (CAGR) of 6.1% • Growth Driver: Rising Cancer Incidence Drives Demand For Effective Radiation Toxicity Treatment Solutions • Market Trend: Innovations In Drug Delivery Systems For Improved Treatment Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Radiation Toxicity Treatment Market?

Radiation toxicity treatment encompasses medical approaches designed to address and mitigate the adverse effects resulting from excessive radiation exposure. These treatments focus on managing symptoms such as fatigue, nausea, and skin injuries, and severe conditions such as damage to organs or bone marrow, with the goal of aiding recovery and reducing long-term health risks. The main products of radiation toxicity treatment market are colony stimulating factors, potassium iodide, prussian blue, diethylenetriamine pentaacetic acid, and others. Colony stimulating factors are biological substances that promote the production of blood cells by stimulating bone marrow activity. These factors are crucial in restoring blood cell counts in conditions that lead to low blood levels, such as during medical treatments. The indications include acute radiation syndrome and chronic radiation syndrome, with radiation types encompassing both ionizing and non-ionizing radiation. It is used in hospitals and research and academic institutes.

What Is The Radiation Toxicity Treatment Market Growth Forecast?

The radiation toxicity treatment market size is expected to see strong growth in the next few years. It will grow to $5.37 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to growing investments in advanced radiation countermeasures, rising demand for rapid-response radiation treatments, expansion of personalized radiation toxicity management, increased focus on long-term survivorship care, ongoing clinical research into novel radioprotective agents. Major trends in the forecast period include increasing development of targeted radioprotective therapies, rising use of colony stimulating factors in treatment protocols, growing focus on bone marrow recovery solutions, expansion of emergency radiation preparedness treatments, enhanced clinical management of acute radiation syndrome.

Global Radiation Toxicity Treatment Market Segmentation

1) By Product: Colony Stimulating Factors, Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Others Products 2) By Indication: Acute Radiation Syndrome, Chronic Radiation Syndrome 3) By Radiation Type: Ionizing Radiation, Accidental And Therapeutic Radiation Exposure 4) By End-User: Hospitals, Research And Academic Institutes Subsegments: 1) By Colony Stimulating Factors: Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) 2) By Potassium Iodide: Oral Potassium Iodide Tablets, Liquid Potassium Iodide Solution 3) By Prussian Blue: Capsules Of Prussian Blue, Prussian Blue Resin 4) By Diethylenetriamine Pentaacetic Acid (DTPA): Calcium DTPA Injection, Zinc DTPA Injection 5) By Other Products: Amifostine, Sodium Bicarbonate, Doxycycline, Activated Charcoal

What Is The Driver Of The Radiation Toxicity Treatment Market?

The increasing prevalence of cancer is expected to propel the growth of the radiation toxicity treatment market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and proliferation of abnormal cells that can invade surrounding tissues and spread to other parts of the body. The increasing prevalence of cancer is attributed to factors such as lifestyle changes, environmental pollution, genetic predisposition, and improved diagnostic capabilities that lead to earlier detection. Radiation toxicity treatment is essential for managing the side effects of radiation therapy in cancer treatment, promoting patient recovery, and minimizing long-term damage. For instance, in August 2024, according to a report published by the Macmillan Cancer Support, a UK-based charitable organization, currently, there are over 3 million individuals living with cancer in the UK, a number projected to increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the increasing prevalence of cancer is driving the growth of the radiation toxicity treatment industry.

Key Players In The Global Radiation Toxicity Treatment Market

Major companies operating in the radiation toxicity treatment market are Pfizer Inc., Merck And Co Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Recipharm AB, Coherus BioSciences Inc., Eckert And Ziegler Strahlen Und Medizintechnik AG, Theragenics Corp., NorthStar Medical Radioisotopes LLC, Fusion Pharmaceuticals Inc., Partner Therapeutics Inc., Heyl Chemisch pharmazeutische Fabrik GmbH And Co KG, Humanetics Corporation, Actinium Pharmaceuticals Inc., Clarity Pharmaceuticals Ltd., Emergent BioSolutions Inc., Bavarian Nordic A S, BTG International Ltd., Jubilant Radiopharma, Cardinal Health Inc.

Global Radiation Toxicity Treatment Market Trends and Insights

Major companies operating in the radiation toxicity treatment market are focusing on technological advancements such as advanced drug delivery systems to improve the precision and effectiveness of treatments, enhance patient compliance, and minimize side effects, ultimately contributing to better therapeutic outcomes and faster recovery times. A drug delivery system is a method that directs medication to specific areas of the body, ensuring proper dosage and effectiveness while reducing unwanted effects. For instance, in December 2023, Coherus BioSciences, a US-based biopharmaceutical company, announced that the U.S. FDA had approved UDENYCA ONBODY, a new on-body injector for pegfilgrastim-cbqv. This device is designed to be used the day after chemotherapy to help reduce the risk of infection caused by febrile neutropenia. The injector administers the medication in just five minutes and features a retractable needle for enhanced safety and comfort. With this approval, Coherus aims to provide a more convenient and user-friendly solution for managing chemotherapy side effects.

What Are Latest Mergers And Acquisitions In The Radiation Toxicity Treatment Market?

In June 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for $2.5 billion. This acquisition aims to enhance the oncology portfolio with advanced radiopharmaceuticals such as FPI-2265, strengthen R&D and manufacturing capabilities, and accelerate the shift to targeted cancer therapies while deepening its presence in Canada. Fusion Pharmaceuticals Inc. is a Canada-based biotechnology company that specializes in developing next-generation radiopharmaceuticals as precision medicines for oncology.

Regional Outlook

North America was the largest region in the radiation toxicity treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Radiation Toxicity Treatment Market?

The radiation toxicity treatment market includes revenues earned by entities by providing services such as blood transfusions, chelation therapy, skin care and burn management, cancer screening, pain management, and bone marrow protection. The market value includes the value of related goods sold by the service provider or included within the service offering. The radiation toxicity treatment market consists of sales of radiation detection and survey devices, personal dosimeters, linear accelerators (LINACs), and neutron capture therapy systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Radiation Toxicity Treatment Market Report 2026?

The radiation toxicity treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the radiation toxicity treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.